Recently, a randomized, double-blind, dose-escalation phase I clinical trial of IONIS ANGPTL3-LRx (a drug targeting hepatic Angptl3 mRNA) was completed in healthy volunteers with elevated TGs and patients with FH to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics (NCT02709850). This evidence concerns the gene ANGPTL3 and familial hyperaldosteronism.